Corneal Edema

A combination of eyelid pressure patching and decellularized, dehydrated pure amniotic membrane basement membrane healed persistent corneal epithelial defects, according to a study published in Ophthalmology and Therapy.

 Alcon has acquired a majority interest in Aurion Biotech, according to a press release.

The Sing IMT improved distance and near vision at 6 months in patients with late-stage age-related macular degeneration, with minimal impact on the corneal endothelium, according to a study published in Heliyon.

Dear phaco companies (I’m talking about you, Alcon, Bausch + Lomb, Johnson & Johnson Surgical Vision and Zeiss),

AURN001, an allogeneic cell therapy candidate, achieved positive results in a phase 1/2 clinical trial for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release from Aurion Biotech.

Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, improved best corrected visual acuity at 6 months and maintained a strong safety profile, according to a press release from Emmecell.

The FDA granted breakthrough therapy and regenerative medicine advanced therapy designations for AURN001 for the treatment of corneal edema secondary to corneal endothelial disease, according to a press release from Aurion Biotech.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS.